Amivantamab-lazertinib shows OS benefit over osimertinib in Asian EGFR-mutant NSCLC subset

This subset analysis of a randomized controlled trial evaluated 629 Asian participants with previously untreated EGFR-mutated, locally advanced or metastatic non-small cell lung cancer. Patients were randomized to receive first-line amivantamab plus lazertinib (n=250), osimertinib (n=251), or lazertinib monotherapy (n=128). The primary outcome for this analysis was overall survival, with a median follow-up of 38.7 months.

The main result showed that amivantamab-lazertinib prolonged overall survival compared to osimertinib, with a hazard ratio of 0.74 (95% CI, 0.56-0.97; nominal P = 0.026). The median overall survival was not reached for the combination therapy group, compared to 38.4 months for the osimertinib group. The 36-month overall survival rate was 61% for amivantamab-lazertinib versus 53% for osimertinib. The safety profile in this Asian subset was reported as consistent with the overall study population, though specific adverse event rates were not reported.

Key limitations include that this is a subset analysis, and the reported P-value is nominal. The median overall survival for the combination arm was not reached, and any projection of a >12-month prolongation is based on an assumption of exponential distribution. The funding source and potential conflicts of interest were not reported. For clinical practice, these results suggest a potential survival benefit for the combination in this specific population, but they should be interpreted with caution pending confirmation from the primary analysis of the full trial population.

Researchers studied whether a combination of two drugs, amivantamab and lazertinib, works better than the standard single drug, osimertinib, for treating a specific type of advanced lung cancer. The study involved 629 Asian patients who had never received treatment for their EGFR-mutant non-small cell lung cancer. They were randomly assigned to receive either the combination therapy, osimertinib alone, or lazertinib alone, and were followed for a median of about 39 months.

The main finding was that patients who received the amivantamab-lazertinib combination lived longer, on average, than those who received osimertinib. The data showed a 26% lower risk of death for the combination group. After three years, 61% of patients on the combination were alive, compared to 53% on osimertinib. The safety of the combination was reported to be consistent with what was seen in the larger trial population, though specific side effect details were not provided in this analysis.

It is important to be careful with these results for a few reasons. This was a subset analysis, meaning it looked at a specific group of patients from a larger trial. The statistical significance was described as 'nominal,' which suggests the finding needs further confirmation. Also, the median survival time for the combination group was 'not reached,' and any projection of how much longer it might be is based on a statistical assumption, not a direct measurement.

For readers, this research suggests the amivantamab-lazertinib combination is a promising first-line treatment option for this specific patient group. However, it is not yet a definitive new standard. Patients should discuss all available treatment options, including potential benefits and side effects, with their oncologist to make the best personal decision.